𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

✍ Scribed by E. Jenny Heathcote; Karen Cauch-Dudek; Valery Walker; Robert J. Bailey; Laurence M. Blendis; Cameron N. Ghent; Pina Michieletti; Gerald Y. Minuk; S. Chris Pappas; Linda J. Scully; Urs P. Steinbrecher; Lloyd R. Sutherland; C. Noel Williams; Helga Witt-Sullivan; Lawrence J. Worobetz; Ruth A. Milner; Ian R. Wanless

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
969 KB
Volume
19
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Ursodeoxycholic acid, a dihydroxyl bile acid normally present in human beings in minimal amounts, becomes incorporated into the bile salt pool when taken orally. In cholestasis, bile acids are retained in the liver and are hepatotoxic. Ursodeoxycholic acid is the least-known hepatotoxic bile acid, has choleretic properties and is reported to benefit patients with chronic cholestasis. In a nationwide Canadian controlled trial, 222 patients with primary biliary cirrhosis were treated with ursodeoxycholic acid (14 mg/kg/body wt/day) or placebo for 24 mo. Only patients with a diagnosis confirmed by liver biopsy and serum positive for antimitochondrial antibodies were enrolled; 88% were symptomatic on entry. The primary outcome measure was percent change in total serum bilirubin from baseline to final follow-up. Treated patients (1 11) and controls (1 11) were comparable with regard to age, gender, biochemical parameters and liver histological condition. Although treatment was not associated with any improvement in symptoms, ursodeoxycholic acid therapy caused the bilirubin to fall significantly within the 6rst 3 m o of therapy (p < 0.001). Significant falls in serum alkaline phosphatase, aminotransferases, cholesterol and IgM levels were also noted in the treated group. Improvement in some histological features was observed but there was no difference between the groups in the number of patients who reached the endpoints of death or liver transplantation. Ursodeoxycholic acid, given to patients with primary biliary

πŸ“œ SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Danyu Lin; Dr Mary F. πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 792 KB

One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, 1 1 vs. stages 111, IV-Ludwig criteria) were randomized within each stratum to ursodiol or placebo given in a s

Ursodeoxycholic acid in the treatment of
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: First controlled data
✍ Marie Borum; Hans Fromm πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 280 KB πŸ‘ 1 views

There is no doubt that further investigations of this phenomenon will be performed and published promptly. Until these questions are answered, we may appreciate the accuracy of Ogden Nash's old observation that "While candy is dandy, liquor is quicker!" 1.

Gabapentin in the treatment of fibromyal
Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial
✍ Lesley M. Arnold; Don L. Goldenberg; Sharon B. Stanford; Justine K. Lalonde; H. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 168 KB πŸ‘ 3 views

## Abstract ## Objective To assess the efficacy and safety of gabapentin in patients with fibromyalgia. ## Methods A 12‐week, randomized, double‐blind study was designed to compare gabapentin (1,200–2,400 mg/day) (n = 75 patients) with placebo (n = 75 patients) for efficacy and safety in treatin

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

A prospective, randomized, double-blind
A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection
✍ Fleckenstein, Jaquelyn F. ;Paredes, Melinda ;Thuluvath, Paul J. πŸ“‚ Article πŸ“… 1998 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 68 KB πŸ‘ 1 views

Acute cellular rejection (ACR) after orthotopic liver transplantation occurs in 50% to 80% of patients despite the recent advances in immunosuppressive therapy. Adjuvant use of ursodeoxycholic acid (UDCA) is theoretically attractive, but studies have shown conflicting results. In this randomized, co